Can we predict who benefits from nivolumab in head and neck cancer?
NCT ID NCT04603248
First seen Feb 13, 2026 · Last updated Jun 20, 2026 · Updated 20 times
Summary
This study looked at 50 people with recurrent or metastatic head and neck squamous cell carcinoma who were treated with nivolumab. Researchers analyzed tumor tissue and blood samples to find immune markers that might predict who responds best to the drug. The goal is to better select patients for this therapy in the future.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Yonsei Severance Hospital
Seoul, South Korea
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab
What this could lead to
If successful, this could help doctors identify which head and neck cancer patients are most likely to benefit from nivolumab, improving treatment outcomes.
What could go wrong
This is a small, completed observational study focused on finding biomarkers, not testing a new treatment. The results may not lead to immediate changes in care.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.